The U.S. insomnia market is categorised into pharmacological treatments and non-pharmacological treatments. The U.S. insomnia pharmacological treatment market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021. The duration of insomnia can be from a day to years. Based on duration, insomnia is divided into three major categories, namely, transient insomnia (less than a month), short term insomnia (between 1 month and 6 months), and chronic insomnia (more than 6 months).
The non-pharmacological treatment market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies. CBTI is highly recommended therapy for insomnia patients followed by hypnotherapy due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly. The other alternative therapies includes exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.
Download FREE Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55727597
The pharmacological treatment market is further segmented into prescription sleep aids and over-the-counter sleep aids. In 2016, the prescription sleep aids segment is expected to hold the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. The prescription sleep aids segment is categorised into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids. Other prescription sleep aids include sleep aids such as antipsychotics, chloral derivatives, and tricyclic antidepressants. The non-benzodiazepines segment is further categorized into zolpidem, eszopiclone, and zaleplon.
The over-the-counter sleep aids segment of U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market includes easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. The OTC sleep aids market is categorised into antihistamines, melatonin, valerian roots, and other herbal & dietary supplements. Other herbal & dietary supplements include sleep aids such as L-theanine, amino acids supplements, and a variety of botanicals. Growing awareness about the advantages of melatonin and valerian roots such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=55727597
The non-pharmacological treatment market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies. CBTI is highly recommended therapy for insomnia patients followed by hypnotherapy due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly. The other alternative therapies includes exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.
Download FREE Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55727597
The pharmacological treatment market is further segmented into prescription sleep aids and over-the-counter sleep aids. In 2016, the prescription sleep aids segment is expected to hold the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. The prescription sleep aids segment is categorised into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids. Other prescription sleep aids include sleep aids such as antipsychotics, chloral derivatives, and tricyclic antidepressants. The non-benzodiazepines segment is further categorized into zolpidem, eszopiclone, and zaleplon.
The over-the-counter sleep aids segment of U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market includes easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. The OTC sleep aids market is categorised into antihistamines, melatonin, valerian roots, and other herbal & dietary supplements. Other herbal & dietary supplements include sleep aids such as L-theanine, amino acids supplements, and a variety of botanicals. Growing awareness about the advantages of melatonin and valerian roots such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=55727597
Comments
Post a Comment